MIF与冠心病心绞痛类型相关性分析被引量：3

Macrophage Migration Inhibitory Factor Correlates with Different Types of Angina with Coronary Heart Disease

下载PDF

导出

摘要目的通过检测血清巨噬细胞移动抑制因子(MIF),探讨冠心病患者不同类型心绞痛及冠脉病变程度与MIF的相关性。方法根据冠脉造影结果,将115例住院患者分为对照组53例和冠心病组62例。冠心病组按Braunwald分类方法,根据临床表现分为稳定型心绞痛组(SAP)10例和不稳定型心绞痛组(UAP)52例,根据Gensini积分法对冠心病患者冠状动脉狭窄程度进行定量评估,采用酶联免疫吸附试验(ELISA)检测两组血清MIF浓度。结果冠心病组(65.94μg/L)MIF水平明显高于对照组(48.08μg/L)。在冠心病组中,UAP组血清MIF浓度明显高于SAP组,同时SAP组和UAP组血清MIF浓度均高于对照组(65.94μg/L vs 48.08μg/L,P<0.05)。不同冠脉病变程度之间血清MIF浓度无统计学差异。结论血清MIF浓度的增高可能与冠心病的发生发展相关,同时MIF水平的高低可以反映冠脉粥样斑块的稳定性,为冠心病的诊断及干预治疗提供依据,但冠脉狭窄程度与血清MIF浓度无明显相关性,不能用于预测冠脉病变情况。 Abstract Objective To test serum macrophage migration inhibitory factor （MIF） and investigate the correlation between different types of angina with coronary heart disease（CHD） patients and coronary artery stenosis severity and MIF. Methods According to the re- suits of coronary angiography（CAG） , 53 patients were diagnosed as the control group and 62 patients were diagnosed as the CHD group. CHD group were further divided into the stable angina pectoris （SAP）group （n = 10）and the unstable angina pectoris （UAP） group（ n = 52） by Braunwald classification method and clinical manifestations. The severity of coronary artery stenosis was quantitative assessed by the Gensini integral method. Enzyme Linked Immunosorbent Assay （ELISA） was used to measure the serum MIF concentration. Results The serum MIF concentration was significantly higher in CHD group（65.94μg/L） than in control group （48.08μg/L）. In the CHD group, the serum MIF concentration was higher in UAP than SAP group, and which in the SAP and UAP group were also higher than con- trol group （65.94μg/L vs 48.08μg/L,P 〈 0.05 ）. The mean level of MIF in different extent of coronary artery lesions was not significant different. Conclusion The increase of MIF level is associated with the occurrence and development of CHD, while the MIF level may re- flect the stability of coronary atherosclerotic plaque, and it can provide the basis for the diagnosis and intervention in the treatment ofCHD. But the MIF level does not significantly correlate with the severity of coronary artery stenosis, and it may not predict the coronary ar- tery disease.

作者王晓艳朱泳金郭辉辉陈鹏官学强杨鹏麟季亢挺唐疾飞

机构地区温州医学院附属第二医院

出处《医学研究杂志》 2013年第11期65-68,共4页 Journal of Medical Research

基金浙江省自然科学基金资助项目(LY13H310006)

关键词冠心病巨噬细胞移动抑制因子稳定型心绞痛不稳定型心绞痛冠脉狭窄程度 Coronary heart disease Macrophage migration inhibitory factor Stable angina pectoris Unstable angina pectoris Coro-nary artery stenosis severity

分类号 R259.414 [医药卫生—中西医结合]

引文网络
相关文献

参考文献15

1Gomez-Guerrero C,Mallavia B,Egido J.Targeting inflammation in Cardiovascular diseases.still a neglected field?[J].Cardiovasc Ther,2012,30(4):189-197.
2Noels H,Bernhagen J,Weber C.Macrophage migration inhibitory factor:a noncanonical chemokine important in atherosclerosis[J].Trends Cardiovasc Med,2009,19 (3):76-86.
3Gibbons RJ,Abrams J,Chatterjee K,et al.ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation,2003,107 (1):149-158.
4Xu X,Wang B,Ye C,et al.Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer[J].Cancer Lett,2008,261 (2):147-157.
5Zernecke A,Bernhagen J,Weber C.Macrophage migration inhibitory vactor in cardiovascular disease[J].Circulation,2008,117:1594-1602.
6Kong YZ,Huang XR,Ouyang X,et al.Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques[J].Cardiovascular Res,2005,65 (1):272-282.
7Yilmaz (O),Kü(c)ük M,Kebap(c)ilar L,et al.Macrophage migration inhibitory factor is elevated in pregnant women with gestational diabetes mellitus[J].Gynecological Endocrinology,2012,28 (1):76-79.
8Ayoub S,Hickey MJ,Morand EF.Mechanisms of Disease:macrophage migration inhibitory factor in SLE,RA atherosclerosis.Nature Clinical Practice[J].Rheumatology,2008,4(2):98-105.
9Andreas S,Jiürgen B,Christian W.Chemokine-like functions of MIF in atherosclerosis[J].Journal of Molecular Medicine,2008,86 (7):761-770.
10Shah PK.Pathophysiology of coronary thrombosis:role of plaque rupture and plaque erosion[J].Prog Cardiovasc Dis,2002,44 (5):357-368.

二级参考文献14

1Hsiang CY, Wu SL, Chen JC, et al. Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-kappaB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: association with the invasive potential. Toxicol Lett, 2007,171:78-86.
2Onodera S, Nishihira J, Iwabuchi K, et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem, 2002, 277:7865-7874.
3Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983, 51:606.
4ACC/AHA Task Force. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures ( Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol, 1988, 12:529-545.
5Surh Y J, Na HK, Lee SS. Transcription factors and mitogenactivated protein kinases as molecular targets for chemoprevention with anti-inflammatory phytochemicals. Biofactors, 2004,21 : 103- 108.
6Dagnell C, Kemi C, Klominek J, et al. Effects of neurotrophins on human bronchial smooth muscle cell migration and matrix metalloproteinase-9 secretion. Transl Res, 2007,150:303-310.
7Luttun A, Lutgens E, Manderveld A, et al. Loss of Matrix metalloproteinase-9 or Matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic aedia destruction but differentially affects plaque growth, Circulation, 2004,109 : 1408-1414.
8Zeng B, Prasan A, Fung KC, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J, 2005,35:331-335.
9Verna L, Ganda C, Stemerman MB. In vivo low-density lipoprotein exposure induces intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 correlated with activator protein-1 expression. Arterioscler Thromb Vasc Biol, 2006,26 : 1344-1349.
10Chandrasekar B, Mummidi S, Mahimainathan L, et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem. 2006,281:15099-15109.